Physician profile
Jonathan A Feld
NPI 1184004806
$6,273.42
in general payments reported to CMS, 2019-2025
19 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.95 · 2020: $214 · 2021: $125 · 2022: $3,599 · 2023: $268 · 2024: $985 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,175 · Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,175.00 |
| Food and Beverage | $1,085.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,500.00 | 2022 | |
| Glaxosmithkline, LLC. | $650.00 | 2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $525.00 | 2024 | Imfinzi |
| Celgene Corporation | $322.38 | 2022-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $235.72 | 2023-2024 | |
| Abbvie INC. | $135.72 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Amgen INC. | $123.46 | 2025 | Blincyto |
| Daiichi Sankyo INC. | $121.57 | 2024-2025 | Vanflyta, Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $119.44 | 2020 | |
| Seagen INC. | $95.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $73.95 | 2019 | |
| Sobi, INC | $68.99 | 2025 | |
| Servier Pharmaceuticals LLC | $63.57 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $52.47 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.48 | 2024 | Xospata |
| Csl Behring | $19.63 | 2022 | |
| Janssen Biotech, INC. | $17.04 | 2025 | Carvykti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Feld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.